Vitamin K2 Supplementation in Adult Episodic Migraine

Arterial Stiffness Clinical Trial

— ViKEM  

Official title:

Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05943457
• Other study ID #: MK7-003
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2023
• Est. completion date: December 2024

Study information

• Verified date: July 2023
• Source: Lebanese American University
• Contact: Sola Aoun Bahous, MD, PhD
• Phone: +9613259450
• Email: sola.bahous[@]lau.edu.lb
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: December 2024
• Est. primary completion date: September 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults aged 18 years or above
• History of episodic migraine with or without aura since > 12 months according to the ICHD-3 criteria.
• Migraine frequency from 4-14 days per month over the 3 months prior to screening.
• Migraine frequency from 4-14 days per month during the baseline period of assessment.
• Successful completion of the migraine diary during the baseline evaluation period.

Exclusion Criteria:

• Migraine patients with superimposed tension type or other forms of primary headaches
• Patients who are currently on any of the migraine prophylactic treatments (Sodium valproate, Topiramate, Beta-blockers, Tricyclic antidepressants, SRNI, Flunarizine, Verapamil, Lisinopril, Candesartan)
• Patients who have been on any of the previously listed medications within 3 months of screening
• Patient who takes the following medications:
• Ergotamine or Triptans > 10 days per month
• NSAIDs or paracetamol > 15 days per month
• Opioids more than 4 days per month
• Patients on anticoagulants
• Other active chronic pain syndromes (i.e. fibromyalgia, painful peripheral neuropathy, post-herpetic neuralgia…)
• History of hypersensitivity to the vitamin K2
• History of soy protein, cheese, eggs and meat allergy
• History of thrombotic events
• Diagnosed coagulopathy or any condition related to coagulation
• Cardiovascular event in the past month
• Current or planned pregnancy
• Lactation
• Inability to tolerate oral medications
• Known intestinal malabsorption or hypomotility syndromes
• Atrial fibrillation
• Active malignancy
• Any acute illness in the past month

Related Conditions & MeSH terms

• Arterial Stiffness
• Headache
• Hypokalemia
• Migraine Disorders
• Migraine Headache
• Vitamin K Deficiency

Intervention

Dietary Supplement:
• Vitamin K2 or menaquinone-7
Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months

Other:
• Placebo
Placebo pills will be administered orally once daily for 6 months

Locations

Country	Name	City	State
Lebanon	Lebanese American University Medical Center - Rizk Hospital	Beirut

Sponsors (3)

Lead Sponsor	Collaborator
Sola Aoun Bahous, M.D. Ph.D.	Lesaffre International, Omicron Pharmaceuticals

Country where clinical trial is conducted

Lebanon, 

References & Publications (6)

Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JE, Rexrode KM. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016 May 31;353:i2610. doi: 10.1136/bmj.i2610. Erratum In: BMJ. 2016 Jun 17;353:i3411. — View Citation

Mansour AG, Ahdab R, Daaboul Y, Korjian S, Morrison DA, Hariri E, Salem M, El Khoury C, Riachi N, Aoun Bahous S. Vitamin K2 Status and Arterial Stiffness Among Untreated Migraine Patients: A Case-Control Study. Headache. 2020 Mar;60(3):589-599. doi: 10.1111/head.13715. Epub 2019 Nov 25. — View Citation

Mansour AG, Hariri E, Daaboul Y, Korjian S, El Alam A, Protogerou AD, Kilany H, Karam A, Stephan A, Bahous SA. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. J Am Soc Hypertens. 2017 Sep;11(9):589-597. doi: 10.1016/j.jash.2017.07.001. Epub 2017 Jul 13. — View Citation

Mozos I, Stoian D, Luca CT. Crosstalk between Vitamins A, B12, D, K, C, and E Status and Arterial Stiffness. Dis Markers. 2017;2017:8784971. doi: 10.1155/2017/8784971. Epub 2017 Jan 12. — View Citation

Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar;27(3):193-210. doi: 10.1111/j.1468-2982.2007.01288.x. — View Citation

Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012 Feb;59(2):186-95. doi: 10.1053/j.ajkd.2011.10.041. Epub 2011 Dec 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes of monthly migraine days	Effect of Vitamin K2 supplementation on the changes from baseline in monthly migraine days as compared to placebo. This will be assessed clinically using a questionnaire to be administered at the start, monthly, and at the end of the study (6 months) about frequency and number of migraine days per month.	6 months
Secondary	Changes from baseline in the headache impact score (HIT-6) as compared to placebo.		6 months
Secondary	Changes from baseline in monthly severe migraine days.	Changes from baseline in monthly severe migraine days as defined by a visual analogue scale rating above 7, as compared to placebo.	6 months
Secondary	Changes from baseline on the modified migraine disability assessment (MIDAS) score as compared to placebo.		6 months
Secondary	Changes from baseline on the modified migraine physical function impact diary (MPFID) as compared to placebo.		6 months
Secondary	Changes from baseline on the quality of life as measure by the EuroQoL compared to placebo.		6 months
Secondary	Changes from baseline of arterial stiffness level.	Changes of arterial stiffness level assessed by measuring the cfPWV using Complior Analyze.	6 months